PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches

Overview

The purpose of this registry is to collect safety and performance data on all commercially available Terumo Aortic knitted and woven grafts, and cardiovascular patches in standard clinical practice. Data will be collected both retrospectively and prospectively.

Full Title of Study: “A Prospective and Retrospective, Multi-Centre, Post-Market, Non-Interventional Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Other
  • Study Primary Completion Date: January 2026

Interventions

  • Device: Gelsoft Plus Vascular Graft
    • Gelatin coated, knitted vascular prosthesis implanted to act as a conduit for channeling blood during repair of damaged or diseased vessels.
  • Device: Vascular Bypass Graft
    • Gelatin coated, knitted vascular prosthesis implanted to act as an extra-anatomical bypass for channeling blood during repair of damaged or diseased vessels.
  • Device: Cardiovascular Patch
    • Cardiovascular knitted polyester patches are frequently used to treat the carotid or femoral arteries to prevent stroke and repair damage to vessels.
  • Device: Gelweave Vascular Graft
    • The Gelweave woven polyester vascular graft allows replacement of large sections of arteries and, following anastomosis to the native blood vessel, provides a stable conduit for blood flow.
  • Device: Gelweave Valsalva Vascular Graft
    • This woven polyester graft is designed to match the aortic root anatomy and is implanted to repair or replace a portion of the aorta in case of an aneurysm, dissection or coarctation at the level of the thoracic aorta.

Arms, Groups and Cohorts

  • Gelsoft Plus – Straights and Bifurcated
    • Patients with aneurysmal or occlusive disease, including those with connective tissue disorders who have received/will receive a Gelsoft Plus Straight or Bifurcate, implanted in the abdomen or peripheral arteries in the last 5 years and from study launch onwards.
  • Gelsoft Plus – Extra-Anatomical
    • Any patients who have received/will receive a Gelsoft Plus Extra-Anatomical supported or unsupported graft, implanted for: axillary-femoral bypass, femoral-femoral bypass or femoral-popliteal bypass in the last 5 years and from study launch onwards.
  • Cardiovascular Patches – Gelseal, Gelsoft, Thin Wall
    • Patients who have been implanted with/require a cardiovascular patch for: thoracic vessel repair with a Gelseal Cardiovascular Patch; abdominal or peripheral vessel repair with a Gelsoft Cardiovascular Patch; or carotid endarterectomy with a Thin Wall Carotid Patch in the last 5 years and from study launch onwards.
  • Gelweave – Abdominal, Thoracic, Thoracoabdominal
    • Patients who, due to either aneurysmal or occlusive disease, have had/require vascular repair of one of the following, implanted in the last 5 years and from study launch onwards: Abdominal aorta, arteries arising from the abdominal aorta or peripheral arteries including femoral, iliac and popliteal arteries. Thoracic aorta or arteries arising from the thoracic aorta. Abdominal and thoracic aorta requiring a thoracoabdominal repair
  • Gelweave – Valsalva
    • Patients who have had/require aortic root repair using valve sparing or valve replacing procedures, with or without replacement of the aortic arch, implanted in the last 5 years and from study launch onwards.

Clinical Trial Outcome Measures

Primary Measures

  • Operative Death
    • Time Frame: 1 Year
    • 30 Day or In-Hospital Mortality
  • Graft Leakage
    • Time Frame: 1 Year
    • Device Failure: The presence of leakage or excessive bleeding through graft/patch

Secondary Measures

  • Device Endpoints
    • Time Frame: 1 Year
    • Device failures, requirement for reintervention or device related adverse events
  • Procedural Endpoints
    • Time Frame: 1 Year
    • Rifampicin or heparin soaking, procedure related adverse events
  • Safety Endpoints
    • Time Frame: 1 Year
    • Occurrence of the following: Mortality, Ischemia, Occlusion, Thrombosis, Haemmorrhage, Rupture, Pseudoaneurysm, Stroke

Participating in This Clinical Trial

Inclusion Criteria

  • Patients must meet all of the following inclusion criteria in order to be eligible for inclusion in the study: All Patients: – Patient meets the minimum age as per local regulations at time of consent – Patient requires treatment with study device(s) according to the IFU(s) – Patient is willing and able to comply with all SOC procedures and study visits – Patient or their legally authorised representative (LAR) has given written informed consent to participate in study, including consent to collect data retrospectively – For prospective emergency patients, retrospective consent is permissible – For retrospective patients who are deceased at time of enrollment, local EC regulations relating to consent process should be followed. Retrospective Patients only: – Patient has a minimum of 1 year post-operative follow-up data available, or complete data to death. – Patient implant date is no more than 5 years prior to study start date. Exclusion Criteria:

  • Any patient who meets any of the following exclusion criteria will be excluded from participation in the study: – Patient is unable or unwilling to comply with the SOC procedures or follow-up regime – Patient is contraindicated per the device IFU – Patient has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre- and post-procedure

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Vascutek Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Clinical Study Manager, +44 141 343 0194, r.smith1@terumoaortic.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.